Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($0.62), $0.41 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $91.5 million versus the consensus estimate of $96.89 million.

2024 R&D and SG&A Expense Guidance
Coherus is introducing a guidance range of combined 2024 R&D and SG&A expenses from $250 to $265 million. This guidance includes approximately $40 million of stock-based compensation expense and excludes the effects of strategic acquisitions, collaborations or investments, the exercise of rights or options related to collaboration programs, and any other transactions or circumstances not yet identified or quantified. This guidance is subject to a number of risks and uncertainties.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.